Episurf Medical announces that the 200th implantation of the Episealer knee implant has been scheduled for the coming days. Episurf Medical’s unique, personalised technology continues to gain traction, enabling orthopaedic surgeons to successfully treat previously difficult to treat patients with cartilage and underlying bone lesions of the knee joint.
“This is a significant milestone for Episurf Medical”, says Pål Ryfors, Acting CEO and CFO of Episurf Medical. “Our 200th Episealer implantation now clearly demonstrates that our technology is being accepted by more and more orthopaedic surgeons with patients continuing to report how our products change their lives”.
Dennis Stripe, Executive Chairman of the Board comments that “Episurf Medical is changing the treatment pathway for patients with knee injuries. Our technology continues to be accepted by specialist surgeons who see for themselves the impact the Episealer has on their patients”.
For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 11 May 2017.